News|Articles|March 26, 2025
Develop Potency Assays Early for ATMP Success
Author(s)Charles River
Early potency assay development and MOA understanding are critical for ATMP success. Delays can increase costs and risk failure, but recent advances highlight the need for timely, validated approaches to ensure regulatory and commercial success.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
5
